IMNM Immunome, Inc.
Financings ·
Immunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments.
Immunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share.
Immunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025.
Immunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.
Immunome is a company with antibody-drug conjugate (ADC) and radioligand programs. Its clinical asset varegacestat, formerly AL102, is an investigational, oral, once-daily GSI therapy under evaluation for desmoid tumors. In December 2025, Immunome reported positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors, and the study met all primary and key secondary endpoints. The company is preparing for a potential commercial launch of varegacestat, subject to regulatory approval, and is investing in commercial supply readiness. Its pipeline also includes IM-3050, a fibroblast activation protein targeted radioligand therapy that received IND clearance in April 2025, with a Phase 1 trial planned for early 2026 after delivery of third-party diagnostic radiotracer supply. Immunome has three preclinical solid tumor ADCs, IM-1617, IM-1340 and IM-1335, with IND submissions anticipated in 2026, and it says its discovery approach centers on designing ADCs against novel or underexplored targets.
| Product or program | What it is | Stage |
|---|---|---|
| Varegacestat (formerly AL102) | Oral once-daily GSI therapy for progressing desmoid tumors | Phase 3 |
| IM-3050 | Fibroblast activation protein targeted radioligand therapy | IND cleared April 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.9 million | $9.0 million |
| Research and development | $177.3 million | $129.5 million |
| Net income (loss) | -$212.4 million | -$293.0 million |
| Cash from operations | -$190.9 million | -$110.8 million |
| Cash and equivalents | $653.5 million | $143.4 million |
| Short-term investments | $0 | $74.0 million |
Our latest story on this, dated Dec 15, 2025: "Immunome proposes $400 million stock offering, later sets $21.50 price". The story links the filing or release it is based on. Read the story.
Immunome, Inc. trades under the ticker IMNM on NASDAQ.
Immunome, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Immunome, Inc. is 1472012. Its filings are on SEC EDGAR.
113,577,629 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Immunome, Inc. under United States.
Our directory classifies Immunome, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Immunome, Inc. is US45257U1088.
aibio.space lists Immunome, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Immunome is a company with antibody-drug conjugate (ADC) and radioligand programs. Its clinical asset varegacestat, formerly AL102, is an investigational, oral, once-daily GSI therapy under evaluation for desmoid tumors.
Varegacestat (formerly AL102): Oral once-daily GSI therapy for progressing desmoid tumors Stage: Phase 3.
IM-3050: Fibroblast activation protein targeted radioligand therapy Stage: IND cleared April 2025.
$6.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Immunome, Inc. reported a net loss of $212.4 million for the fiscal year ended Dec 31, 2025, and used $190.9 million of cash in operations, per its annual report to the SEC.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio